News | August 03, 2025
Illumina launches new assay for tumor profiling
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
Sam Samad will be departing Illumina on July 8, 2022, after serving as CFO for more than five years.
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
In numerous neurological and rare disorders, where clinical characteristics can be confusing, NGS-based approaches have demonstrated considerable increases in disease detection rates over other approaches
Most recently, Rollins was the Chief Information Officer at UnitedHealthcare
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
_logo_256_384.jpg){kind=logo}
It supports sequencing-based COVID 19 surveillance in India
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Subscribe To Our Newsletter & Stay Updated
